Pierre Feugier

32PUBLICATIONS
361CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical biotechnology diagnostics (incl. biosensors)Haematological tumoursEpigenetics (incl. genome methylation and epigenomics)Cardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Jul 14, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

|May 14, 2026
Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).

|Mar 31, 2026
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Nicolas Gower, Pierre Feugier, Jason R Westin

|Nov 03, 2025
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.

Mouhamad Khouja, Elisa Genuardi, Simone Ferrero

|Sep 13, 2025
Intensive Treatment in Adult Burkitt Lymphoma with Lymphome Malin B (LMB) Regimen: Excellent Outcomes Despite Substantial Toxicity and Supportive Care Demands.

Ivan Dlouhy, Diana Viegas, Inês Coelho

|Jan 22, 2025
Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL.

Sarka Pavlova, Jitka Malcikova, Lenka Radova

Pageof 6

Frequent Collaborators

9 joint publications

Oliver A Cornely

9 joint publications

Livio Pagano

9 joint publications

Jon Salmanton-García

9 joint publications

Francesco Marchesi